PRAME and diffuse large B-cell lymphoma: This long-term effect of EZH2i is consistent with the immune reactivation observed after completion of the treatment cycle and highlights the potential significance of upregulation of PRAME and other immune modulatory genes that are silenced by mutant EZH2 in DLBCL cells.